secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2024-09-24T23:59:59+00:00
Accession:  0001193125-24-224116
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences reports positive interim Phase 2 data for WVE-N531: adjusted dystrophin 9.0% in DMD exon 53
--------------------------------------------------------------------------------

- Mean muscle content-adjusted dystrophin expression 9.0% (range 4.6-13.9%); unadjusted 5.5% (range 3.3-8.3%) in ambulatory boys.
- Dystrophin isoforms consistent with milder Becker DMD; 89% of ambulatory participants achieved ≥5% adjusted dystrophin.
- WVE-N531 safe and well tolerated; all treatment-related AEs mild, no serious AEs or discontinuations.
- Muscle concentration ~41,000 ng/g; 61-day half-life supports monthly dosing; preclinical data suggest higher concentration in heart/diaphragm.
- Wave expects regulatory feedback and complete 48-week FORWARD-53 data in 1Q 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524224116/0001193125-24-224116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312524224116/d876211d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-224116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer